What Are Biotechs Good At?
Executive SummaryBiotech companies have seen themselves as proto-drug companies. But the real talents of many of them have little to do with becoming fully integrated discovery-based drug firms. They should be performing core-competency reviews to uncover their real distinctive talents, and then exploiting them--talents which may lie in dealmaking (e.g., only one of Chiron's three main products comes from its internal research), marketing (e.g., perhaps Genentech's best skill is differentiating its drugs from cheaper alternatives), clinical development, or even distribution (a la Axion).
You may also be interested in...
The US Senate’s vote to approve legislation underpinning the US-Mexico-Canada trade agreement has been welcomed by the country’s off-patent industry.
By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.